Prevalence of Psychotropic Medication Use and Psychotropic Polypharmacy in Autistic Adults With or Without Intellectual Disability

被引:2
作者
Yoshida, Kazunari [1 ,2 ,3 ]
Lunsky, Yona [1 ,4 ]
Mueller, Daniel J. [2 ,4 ,5 ]
Desarkar, Pushpal [1 ,4 ,5 ,6 ]
机构
[1] Ctr Addict & Mental Hlth, Azrieli Adult Neurodev Ctr, 1025 Queen St West, Toronto, ON M6J 1H4, Canada
[2] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Tanenbaum Ctr Pharmacogenet, Toronto, ON, Canada
[3] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[4] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[5] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
[6] Ctr Addict & Mental Hlth, Adult Neurodev Serv, Toronto, ON, Canada
关键词
Autism spectrum disorder; Intellectual disability; Psychotropic medication use; Psychotropic polypharmacy; CHALLENGING BEHAVIORS; PSYCHIATRIC-DIAGNOSIS; SPECTRUM DISORDER; CHILDREN; ADOLESCENTS; PREDICTORS; INDIVIDUALS; MANAGEMENT; PATTERNS; COUNTY;
D O I
10.1007/s10803-023-06208-y
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
The aim of this study was to compare the rates of psychotropic medication use and psychotropic polypharmacy between autistic adults with and without intellectual disability (ID) and to examine factors associated with psychotropic medication use and psychotropic polypharmacy in autistic adults, stratified by the presence of ID. We conducted a retrospective medical chart review of outpatients with an autism diagnosis aged 18 years and older. The rates of psychotropic medication use and psychotropic polypharmacy were compared between autistic adults with and without ID. Subsequently, logistic regression analyses were performed to identify factors associated with psychotropic medication use and psychotropic polypharmacy in autistic adults with ID and those without ID, respectively. The rates of prevalence of psychotropic medication use and polypharmacy were significantly higher in participants with ID than those without ID (78.6% vs. 58.8% and 49.3% vs. 31.2%; p-values < 0.05). Age, gender, race, residence, presence of mood disorders, presence of schizophrenia, absence of anxiety disorder, number of psychiatric comorbidities, and presence of behaviors that challenge were significantly associated with these outcomes, depending on the presence/absence of ID. The need to optimize pharmacotherapy in autistic adults, stratifying by the presence of ID, is highlighted.
引用
收藏
页码:457 / 471
页数:15
相关论文
共 49 条
  • [1] Medication patterns in patients with autism: Temporal, regional, and demographic influences
    Aman, MG
    Lam, KSL
    Van Bourgondien, ME
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (01) : 116 - 126
  • [2] Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio
    Aman, MG
    Lam, KSL
    Collier-Crespin, A
    [J]. JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2003, 33 (05) : 527 - 534
  • [3] American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders, V5th
  • [4] [Anonymous], 2015, Challenging behaviour and learning disabilities: Prevention and interventions for people with learning disabilities whose behaviour challenges
  • [5] [Anonymous], 2012, Autism spectrum disorder in adults: Diagnosis and management
  • [6] Bertelli MO., 2022, TXB PSYCHIAT INTELLE
  • [7] Prevalence of Challenging Behaviour in Adults with Intellectual Disabilities, Correlates, and Association with Mental Health
    Bowring, Darren L.
    Painter, Jon
    Hastings, Richard P.
    [J]. CURRENT DEVELOPMENTAL DISORDERS REPORTS, 2019, 6 (04) : 173 - 181
  • [8] Psychiatric Comorbidity and Medication Use in Adults with Autism Spectrum Disorder
    Buck, Tara R.
    Viskochil, Joseph
    Farley, Megan
    Coon, Hilary
    McMahon, William M.
    Morgan, Jubel
    Bilder, Deborah A.
    [J]. JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2014, 44 (12) : 3063 - 3071
  • [9] Use of Psychotropic Medication in Children and Adolescents With Autism Spectrum Disorders
    Coury, Daniel L.
    Anagnostou, Evdokia
    Manning-Courtney, Patricia
    Reynolds, Ann
    Cole, Lynn
    Mccoy, Robin
    Whitaker, Agnes
    Perrin, James M.
    [J]. PEDIATRICS, 2012, 130 : S69 - S76
  • [10] Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability
    de Kuijper, G. M.
    Hoekstra, P. J.
    [J]. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2017, 61 (10) : 899 - 908